Tweets
#ACR22 Best in PsA and SpA - new Rxs, unraveling responses to Rx by sex/gender. X-ray inhibition w SpA drugs is a reality. Nice peeps working in these areas @RheumNow @ACRheum https://t.co/8VfdyyHPZi
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Bihlet et al. Anti-histamines may reduce structural progression of knee OA. Post-hoc analysis of 2 trials @RheumNow #ACR22 Abstr#1893 https://t.co/RrrelHDz75 https://t.co/Sf7RpjjAaN
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action?
@RheumNow ABST0297 #ACR22
https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Shanahan et al. RCT of Genicular nerve block for knee OA. It works but temporary, with loss of effect by week 12. @RheumNow #ACR22 Abstr#1892 https://t.co/VySjBGrVeR https://t.co/JNKQeOVB6z
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than other DMARDs which were continued (mostly RTX/MMF).
Good to see more direct data rather than having to extrapolate from flu.
@RheumNow ABST0913 #ACR22
https://t.co/YphKywNJfA
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Please find our Day 2 #ACR22 Daily Recap Video by @RheumNow Faculty
https://t.co/f3BbKkgzRp
@Janetbirdope @synovialjoints @doctorRBC @bella_mehta @AkhilSoodMD @RHEUMarampa @DrCassySims https://t.co/VZM53cUyWL
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
Ho et al. Consistent colchicine use assoc reduction in MACE in patients with gout and pre-existing CVD. @RheumNow #ACR22 Abstr#1815 https://t.co/tXwa2FrSrp https://t.co/8TKl4z7iaH
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Kastrati et al. Case series immune apheresis in IIM. 24 patients. Reduced CK in 21/24, 971 to 347. Reduced steroid 25%, median 12.5mg reduction @RheumNow #ACR22 Abstr#1882 https://t.co/UUlm4xEX61 https://t.co/bS2IA9OKnH
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
